lungsflow

99 results found.

Top Stocks matching your search for "lungs flow"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
AVXL

Anavex Life Sciences Corporation

-22.55%

$11.75 - $9.10

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 23, 2023

“Statistically significant improvements in lung fu... See more

Jan, 17, 2023

there could be a cure/preventative for breast cancer out there

02/1002/1502/2102/2403/0103/0603/0903/1403/1703/22
SLRX

Salarius Pharmaceuticals Inc

-8.52%

$2.23 - $2.04

Feb 8th 2023 - Mar 22nd 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Oct, 28, 2022

$SLRX “These initial data explain why we believ... See more

Oct, 28, 2022

$SLRX SP-3164 showed significant tumor growth &q... See more

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
TGTX

TG Therapeutics Inc

-19.05%

$18.43 - $14.92

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 21, 2023

$TGTX MOST CONVENIENT- 50% faster infusion SAFE... See more

Mar, 13, 2023

INFUSION TIME 3.NO BREAST CANCER ISSUES 4.

AVXL

Anavex Life Sciences Corporation

-22.55%

$11.75 - $9.10

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 23, 2023

“Statistically significant improvements in lung function, symptoms and quality of life 36% reduction in rate of exacerbations over 24 weeks Well tolerated safety profile over 48 weeks NDA submission planned for 1H 2023” Oh, 48 weeks! !

Jan, 17, 2023

there could be a cure/preventative for breast cancer out there

Jan, 13, 2023

They have a great product treating cancer with immunotherapy, peer reviewed journal

Jan, 7, 2023

Alzheimer therapies are on the top of choices.

Jan, 6, 2023

A drug that actually helps without any major side effects .. and breakthrough therapy. .

Dec, 7, 2022

Better than chemo.

Dec, 3, 2022

$AVXL The oral Anavex 2-73 therapy met the primary and secondary endpoints of the trial, with patients receiving the therapy experiencing statistically significant improvement in cognition.

SLRX

Salarius Pharmaceuticals Inc

-8.52%

$2.23 - $2.04

Feb 8th 2023 - Mar 22nd 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Oct, 28, 2022

$SLRX “These initial data explain why we believe SP-3164 is so exciting, with the potential to make a positive difference in the treatment of hematologic cancers.

Oct, 28, 2022

$SLRX SP-3164 showed significant tumor growth "inhibition" in in vivo studies including statistically significant improvement over the approved immunomodulatory drugs lenalidomide (Revlimid®) and pomalidomide (Pomalyst®)

TGTX

TG Therapeutics Inc

-19.05%

$18.43 - $14.92

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 21, 2023

$TGTX MOST CONVENIENT- 50% faster infusion SAFEST - Zero Breast Cancer Risk MOST AFFORDABLE - By far If TGTX was a Big Pharma Company, the medical press would be blowing it up with praise.

Mar, 13, 2023

INFUSION TIME 3.NO BREAST CANCER ISSUES 4.

Feb, 3, 2023

- Lowest ARR rate, no black box label, reduced brain lesions, and no reports of breast cancer.

Jan, 27, 2023

Lowest ARR rate, no black box warning label, reduced brain lesions, and no reports of breast cancer (there are reports of breast cancer with other MS treatments, and 75% of people with MS are women).

Jan, 16, 2023

$TGTX "4 Stories of Living with Multiple Sclerosis" Briumvi, the best and most affordable, 1HR infusion, no black box label warning, and no warning or report of causing breast cancer.

Jan, 12, 2023

No breast cancer risk.

Jan, 10, 2023

Major upgrade for patients and infusion centers -No major health threats like breast cancer or sever liver damage like main competition

Jan, 6, 2023

$TGTX possibly the best therapy available for MS patients that exists today!

Jan, 5, 2023

MS is 3 times more common in women and there were no reports of breast cancer compared to the competition!